This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

3 Stocks Under $5 Making Big Moves

Stocks in this article: ROSG IMUC OXGN

ImmunoCellular Therapeutics

ImmunoCellular Therapeutics (IMUC) is a development-stage company which is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. This stock is trading up 7.8% to $2.34 in recent trading.

Today's Range: $2.24-$2.39

52-Week Range: $1.51-$4.00

Volume: 1.07 million

Three-Month Average Volume: 435,416

From a technical perspective, IMUC is ripping higher here right above its 50-day moving average of $2.05 with monster upside volume. This move has started to push shares of IMUC into breakout territory, since the stock has taken out some near-term overhead resistance levels at $2.27 to $2.28. Shares of IMUC are now quickly moving within range of another near-term breakout trade. That trade will hit if IMUC manages to take out its 200-day moving average of $2.65 with high volume.

Traders should now look for long-biased trades in IMUC as long as it's trending above $2.27 to $2.28, and then once it sustains a move or close above its 200-day at $2.65 with volume that hits near or above 435,416 shares. If that breakout hits soon, then IMUC will set up to re-test or possibly take out its next major overhead resistance levels $2.93 to $2.94. Any high-volume move above those levels will then put $3.26 to $3.50 into range for shares of IMUC.

Rosetta Genomics

Rosetta Genomics (ROSG) develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2 / mets, miRview squamous, miRview meso and miRview kidney. This stock is trading up 2% to $4.63 in recent trading.

Today's Range: $4.65-$4.76

52-Week Range: $1.40-$23.43

Volume: 136,000

Three-Month Average Volume: 553,442

From a technical perspective, ROSG is moving modestly higher here back above its 50-day moving average of $4.61 with lighter-than-average volume. This move is quickly pushing shares of ROSG within range of triggering a near-term breakout trade. That trade will hit if ROSG manages to take out some near-term overhead resistance levels at $4.95 to $5 with high volume.

Traders should now look for long-biased trades in ROSG as long as it's trending above its 50-day at $4.61, and then once it sustains a move or close above those breakout levels with volume that hits near or above 553,442 shares. If that breakout triggers soon, then ROSG will set up to re-test or possibly take out its next major overhead resistance levels at $5.50 to $5.98. Any high-volume move above $5.98 will then put $6.27 to $7 into range for shares of ROSG.

To see more stocks that are making notable moves higher today, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs